Growing Development in The Drugs Coupled with Technological Advancement in the Treatment of Cluster Headache Augmenting The Growth of the Cluster Headache Treatment Market

The growing development in the drugs and technological advancement in the treatment of cluster headache is the major factor encouraging the growth of the global cluster headache treatment market. For instance, in June 2019, Eli Lilly and Co. granted the US Food and Drug Administration (FDA) approval for Emgality (Galcanezumab). The drug that helps in decreasing the frequency of attacks in episodic cluster headache patients. It is the first FDA approved drug for the treatment of Episodic Cluster Headache. It helps in reducing the chances of migraines in cluster headache affected patients. The safety of Emgality was evaluated in three clinical trials that include more than 2,500 patients. The hypersensitivity reaction has been reported with Emgality in clinical studies.  The most common reaction with the use of Emgality is injection site reactions.

Browse the full report description Cluster Headache Treatment Market Size, Share, & Trend Analysis Report, By Treatment (Drug (Triptans, Octreotide, Dihydroergotamine, and Others) and Device), and Forecast Period 2019-2025 at https://www.omrglobal.com/industry-reports/cluster-headache-treatment-market 

In April 2017, ElectroCore Medical plc received approval for GammaCore devices from the US FDA. GammCore is a non-invasive vagus nerve stimulator designed with the aim to cure pain in the episodic cluster headache in adults. It is the first FDA approved device used for the treatment of episodic cluster headache. GammaCore is a safe, efficient, and effective way for the treatment of cluster headache with respect to other available treatments. The FDA approved gammCore has the new technological advancement in the treatment of pain associated with the cluster headache. It does not have any side effects of using this device and also there is no dose limit for it as it was prescribed for other cluster headache treatments.

In September 2018, ElectrCore started serving its episodic cluster treatment with GammaCore sapphire therapy in the US to expand its geographical presence as the US has the huge market for cluster headache treatment with around more than 0.35 million people suffering from cluster headache provides a huge opportunity for the company as well as the market to grow.

In March 2017, Autonomic Technologies announced the received of expanded indication (CE) mark in Europe for the Pulsante SPG Microstimulator Systems. Pulsante SPG Microstimulator Systemis the first implantable neurostimulation therapy to receive CE mark for pain relief in both cluster headache and certain types of migraine. The Pulsante SPG Microstimulator System is activated using an external remote controller that enables the patient to deliver as-needed stimulation to relieve the attack. 

Cluster Headache Treatment Market Segmentation

By Treatment 

• Drug

o Triptans

o Octreotide

o Dihydroergotamine

o Others

• Devices 

Cluster Headache Treatment Market – Segment by Region